Every year, the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) brings together experts in infectious diseases and clinical microbiology, including many ARLG members. ESCMID Global 2026 is being held on April 17-21 in Munich, Germany, with live streaming of sessions for virtual attendees. Check out the list below of ARLG members who are speaking or chairing events. For the full schedule with more details about each of these sessions, visit the ESCMID Global Congress program page.
ARLG Member Presentations at ESCMID Global 2026
| Date | Time (CEST) | Session Number & Title | Presentation Title | Speakers | Chair |
|---|---|---|---|---|---|
| 4/17/2026 | 8:30-10:30 | EWOO5: Prevention and treatment for specific intra-abdominal infections | Selective decontamination: benefits and resistance development | Nick Daneman | |
| 4/17/2026 | 17:30-18:30 | ME029: Overcoming challenges to implementing system-wide antimicrobial stewardship | Sara Cosgrove | ||
| 4/18/2026 | 13:30-14:30 | JS001: Late-breaking research from JAMA: novel insights on treating and preventing infections around the world | Dalbavancin pharmacokinetics in complicated Staphylococcus aureus bacteraemia. A secondary analysis of the DOTS randomised clinical trial | Thomas Holland | |
| 4/18/2026 | 13:30-14:30 | JS001: Late-breaking research from JAMA: novel insights on treating and preventing infections around the world | Rapid susceptibility testing for bacteremia | Ritu Banerjee | |
| 4/18/2026 | 16:15-18:15 | EW071: Adaptive platform trials in infectious diseases | BALANCE PLUS: a platform trial answering challenging questions on Gram-negative infections | Nick Daneman | |
| 4/18/2026 | 16:15-18:15 | SY063: Cracking the phage code: from clinical insights to precision design | Designing clinical trials around phage therapy | Pranita Tamma | |
| 4/19/2026 | 11:00-12:00 | SY086: Therapeutic management of carbapenem-resistant Gram-negative infections: where are we globally? | Pranita Tamma | ||
| 4/19/2026 | 13:30-14:30 | FO096: Communicating science today: new media, new platforms | Angela Huttner | ||
| 4/20/2026 | 8:30-10:30 | SY115: Interconnected microbiomes and resistomes across One Health | Hospital microbiomes as hotspots for emerging resistance: surveillance-to-intervention | Amy Mathers | |
| 4/20/2026 | 13:30-15:30 | LB007: The trial run | Angela Huttner, David Paterson | ||
| 4/20/2026 | 13:30-15:30 | SY132: Innovative methodologies for advancing PK/PD studies | Multi-Omics approaches to personalise and improve antibiotic efficacy | Gauri Rao | |
| 4/21/2026 | 8:30-10:30 | CGR: Clinical Grand Rounds | David Paterson | ||
| 4/21/2026 | 11:00-12:00 | OS135: Harnessing wastewater for surveillance of AMR | Amy Mathers | ||
| 4/21/2026 | 13:30-15:30 | EW169: UTIs off the beaten path: complex patients, complex choices | Angela Huttner |
ARLG Member Posters at ESCMID Global 2026
| Date | Time (CEST) | Abstract/Poster Title | Authors | Presenter |
|---|---|---|---|---|
| 4/20/2026 | 16:51 | E0784: ePoster Flash - Randomised, double-blind, placebo-controlled trial of the safety and microbiological activity of bacteriophage therapy in cystic fibrosis participants chronically colonised with Pseudomonas aeruginosa | P. Tamma, T. Hamasaki, M. Souli, D. Van Tyne, D. Pride, S. Nayak, K. Moon, E. Raterman, K. Greenwood- Quaintaince, D. Ellison, A. Filippov, M. Nikolich, T. Lodise, D. Conrad, A. Jaunarajs, Z. Wintrob, D. Albon, P. Allyn, T. Barto, J. Billings, L. Caverly, A. Graham, W. Hunt, R. Jain, J. Koff, K. Mcbennett, D. Miller, P. Mohabir, B. Morrissey, K. Patel, J. Wang, N. West, M. Bates, J. Leonard, G. Sah, M. Chiu, B. Evans, H. Geres, C. Koscianski, U. Rappo, J. Fackler, H. Chambers, S. Evans, R. Patel, V. Fowler, R. Schooley | Pranita Tamma |
| 4/20/2026 | 12:00-13:30 | P1539: Poster - Fast Antibiotic Susceptibility Testing for Gram-Negative Bacteremia (FAST): Multinational Randomized Controlled Trial Evaluating a Rapid Phenotypic Susceptibility Test Performed on Positive Blood Cultures | R. Banerjee, L. Komarow, Y. Li, D. Mau, A. Dodd, H. Geres, K. Greenwood-Quaintance, A. Adler, S. Baliga, M. Chowers, G. Chrysos, M. Paul, S. Pournaras, DS. Regueiro, S. Evans, H. Chambers, V. Fowler Jr, R. Patel, on behalf of the Antibacterial Resistance Leadership Group | |
| 4/19/2026 | 12:00-13:30 | P2785: Poster - Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: PKonnecting the DOTS | TP. Lodise, T. Hamasaki, NA Turner, N. Fishbane, L. Ge, Q. Wu, L. Zeng, T. Riccobene, R. Patel, U. Rappo, S. Evans, VG. Fowler Jr, HF. Chambers, and TL. Holland on behalf of the Antibacterial Resistance Leadership Group | |
| 4/19/2026 | 12:00-13:30 | P3094: Poster - Economic Outcomes with Dalbavancin versus Standard of Care in Complicated Staphylococcus aureus Bacteremia: Findings from the DOTS Trial | Y. Li, SD. Reed, DK. Pasquale, NA. Turner, R. Drew, P. Cook, S. Zaharoff, VG. Fowler, TL. Holland |